{"product_id":"oakstone-the-brigham-and-dana","title":"Oakstone The Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology 2022","description":"\u003ch4 class=\"product_title entry-title\"\u003eOakstone The Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology 2022\u003c\/h4\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cstrong\u003eInclude: 61 videos + 2 pdfs, size: 8.53 GB\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Target Audience: fellows\/trainees, practicing hematology and oncology\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003e Sample video: for sample video\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cstrong\u003e Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"form-group\"\u003e\n\u003cdiv class=\"form-control-plaintext\"\u003e\n\u003cdiv class=\"form-group\"\u003e\n\u003ch3\u003eElevate Your Hematology and Oncology CME\u003c\/h3\u003e\n\u003cem\u003eThe Brigham and Dana-Farber Board Review and Comprehensive Update in Hematology and Oncology \u003c\/em\u003eis a case-based online CME course focused on improving overall knowledge and clinical competency. Prep for your board exam and stay current on basic principles, changing guidelines and therapeutic strategies. Practice improvement areas featured in the continuing medical education program include:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eAcquired\/Congenital Bone Marrow Failure\u003c\/li\u003e\n\u003cli\u003eThalassemia\/Hemoglobinopathies\u003c\/li\u003e\n\u003cli\u003eTransfusion Medicine\u003c\/li\u003e\n\u003cli\u003eNew Therapies (Pharmacology)\u003c\/li\u003e\n\u003cli\u003eInfections of the Immunocompromised\u003c\/li\u003e\n\u003cli\u003eHematologic Malignancies (Acute\/Chronic Leukemias; Myeloma\/Lymphomas)\u003c\/li\u003e\n\u003cli\u003eThoracic Oncology (Head\/Neck\/Lung\/Thyroid)\u003c\/li\u003e\n\u003cli\u003eand many more…\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cstrong\u003eDate of Original Release:\u003c\/strong\u003e June 30, 2022\u003cbr\u003e\u003cstrong\u003eTermination Date: \u003c\/strong\u003eJune 30, 2025\u003cbr\u003e\u003ch3\u003eLearning Objectives\u003c\/h3\u003e\n\u003cem\u003eAt the conclusion of this activity, the participant will be able to:\u003c\/em\u003e\n\u003cbr\u003e\u003cul\u003e\n\u003cli\u003eApply current\/recommended hematology and oncology guidelines in clinical practice\u003c\/li\u003e\n\u003cli\u003ePerform differential diagnosis of complex clinical presentations related to hematologic and oncologic disorders\u003c\/li\u003e\n\u003cli\u003eIdentify\/apply current therapeutic options for specific hematologic and oncologic disorders\u003c\/li\u003e\n\u003cli\u003eReview and interpret up-to-date literature relevant to clinical practice in hematology and oncology\u003c\/li\u003e\n\u003cli\u003eDemonstrate knowledge of pathophysiology as it applies to management of hematology and oncology disorders\u003c\/li\u003e\n\u003cli\u003eApply knowledge gained to the ABIM certification\/recertification hematology and oncology examinations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3\u003eIntended Audience\u003c\/h3\u003e\n\u003cbr\u003eThe activity was planned for fellows\/trainees, practicing hematology and oncology specialists (MDs), and other professional affiliates (internists with an interest in hematology and oncology) who are preparing to take ABIM board review or recertification examinations, or who seek CME activities to improve patient care in the areas of hematology and oncology medicine.\u003cbr\u003e\u003cbr\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003eTopics:\u003c\/strong\u003e\n\u003cbr\u003e\u003cp style=\"padding-left: 40px;\"\u003e1. Molecular Genetics of Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e2. Advances in Cancer Drug Development Part I – Chemotherapy _ Targeted Agents.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e3. Advances in Cancer Drug Development Part II – Modulation of the Tumor Microenvironment.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e4. Infections in Cancer Patients.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e5. Symptom Management in Patients with Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e6. Communication The Key to Excellence in End-of-Life Care.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e7. Biology of Hematopoietic Stem Cell Transplantation.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e8. Biology of Acute Leukemia and Myelodysplastic Syndromes.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e9. Acute Leukemias.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e10. Myelodysplastic Syndrome.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e11. Chronic Myelogenous Leukemia.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e12. Myeloproliferative Syndromes.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e13. Multiple Myeloma.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e14. Waldenstrom Macroglobulemia and Amyloidosis.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e15. Low Grade Lymphomas.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e16. Aggressive Non-Hodgkin Lymphoma.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e17. Hodgkin’s Lymphoma.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e18. Diagnosis and Treatment of CLL and Related B Cell Malignancies.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e19. Head and Neck Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e20. Natural History, Screening, and Small Cell Lung Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e21. Non Small Cell Lung Cancer – Part 1.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e22. Non Small Cell Lung Cancer – Part 2.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e23. Mesothelioma and Thymoma.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e24. Carcinoid and Neuroendocrine Tumors.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e25. Novel Approaches for the Management of Esophageal and Gastric Cancers.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e26. Pancreatic Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e27. Hepatobiliary Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e28. Anal Cancer _ Colorectal Cancers Part 1.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e29. Colorectal Cancers Part 2.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e30. Gastrointestinal Cancer Genetic Syndromes.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e31. Testicular Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e32. Renal and Bladder Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e33. Prostate Cancer Part I Overview and Management of Localized Disease.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e34. Prostate Cancer Part II Management of Disseminated Prostate Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e35. Melanoma.mp\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e36. Sarcomas _ Gastrointestinal Stromal Tumors (GIST).mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e37. Molecular Advances and Emerging Treatment Strategies in Ovarian Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e38. Cervical _ Endometrial Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e39. Neuro-oncology.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e40. Breast Cancer – Risk Factors, Genetics, Screening, and Prevention.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e41. Multimodality Therapy for Early Stage Breast Cancer Part 1 – Surgery and Radiation.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e42. Multimodality Therapy for Early Stage Breast Cancer Part 2 – Systemic Therapy.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e43. Management of Metastatic Breast Cancer.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e44. Breast Cancer Survivorship.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e45. Hematopoiesis and Cytokines.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e46. Acquired Bone Marrow Failure.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e47. Congenital Bone Marrow Failure.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e48. Hemophagocytic Syndromes and Related Immunodeficiencies.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e49. Anemia – An Overview .mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e50. Iron Deficiency and Iron Overload.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e51. Immune Hemolytic Anemia.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e52. Non-immune Hemolytic Anemia.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e53. Sickle Cell Disease.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e54. Thalassemia and Other Hemoglobinopathies.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e55. Disorders of Neutrophils.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e56. Acquired Thrombocytopenias.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e57. Hemophilia.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e58. Von Willebrand Disease _ Congenital Platelet Disorders.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e59. Congenital and Acquired Thrombophilia.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e60. Use of Direct Oral Anticoagulants in Clinical Practice.mp4\u003c\/p\u003e\n\u003cp style=\"padding-left: 40px;\"\u003e61. Transfusion Medicine for the Clinician.mp4\u003c\/p\u003e\u003cbr\u003e476-Questions.pdf\u003cbr\u003e\u003cbr\u003e476-Syllabus.pdf","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954400989282,"sku":"MED-AMB02741","price":20.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Oakstone-The-Brigham-and-Dana-Farber-Board-Review-and-Comprehensive-Update-in-Hematology-and-Oncology-2022-300x300-1.jpg?v=1779375487","url":"https:\/\/meducourse.com\/products\/oakstone-the-brigham-and-dana","provider":"Meducourse","version":"1.0","type":"link"}